MedTrace Logo

Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

NCT04798898 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-12-05

No results posted yet for this study

Summary

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.

Conditions

  • Liver Metastasis Colon Cancer

Interventions

DEVICE

RFA (radiofrequency ablation)

Preoperative RFA-induced partial necrosis of the liver metastasis

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Frank V Mortensen, MD, DMSc · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2025-06-01
Completion
2026-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04798898 on ClinicalTrials.gov